<DOC>
	<DOCNO>NCT01245049</DOCNO>
	<brief_summary>The purpose study compare immunogenicity safety booster dose BoostrixTM Polio Sanofi Pasteur MSD 's RepevaxTM , co-administered second dose PriorixTM , healthy 3 4-year-old child .</brief_summary>
	<brief_title>Immunogenicity Safety GSK Biologicals ' Boostrix Polio Vaccine 3 4-year-old Children</brief_title>
	<detailed_description />
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) ( LAR ) comply requirement protocol enrol study . A male female child 3 4 year age time booster vaccination ( , exclude 5 year age ) . Subjects receive complete threedose primary vaccination diphtheriatetanusacellular pertussis ( DTPa ) vaccine inactivate poliovirus ( IPV ) vaccine first six month life , line recommendation United Kingdom ( UK ) . Subjects receive first dose live attenuate measlesmumpsrubella vaccine within second year life , line recommendation UK . Written inform consent obtain parent ( ) /LAR ( ) subject time enrolment . Healthy subject establish medical history clinical examination enter study . Child care . Use investigational nonregistered product study vaccine ( ) within 30 day precede booster dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior booster vaccine dose . Administration vaccine foreseen study protocol within 30 day prior vaccination , plan administration study period , exception inactivate influenza vaccine . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Previous booster vaccination diphtheria , tetanus , pertussis , poliomyelitis since primary vaccination first year life . Previous measles , mumps and/or rubella second dose vaccination . Evidence previous intercurrent diphtheria , tetanus , pertussis , poliomyelitis , measles , mumps and/or rubella disease . Known exposure measles , mumps and/or rubella within 30 day prior study start . Any confirm suspected immunosuppressive immunodeficiency condition , base medical history physical examination . History reaction hypersensitivity likely exacerbate component vaccine . Administration immunoglobulin and/or blood product within three month precede booster dose plan administration study period . Occurrence transient thrombocytopenia neurological complication follow early immunisation . Occurrence follow adverse event previous administration DTP vaccine : Hypersensitivity reaction component vaccine ; Encephalopathy unknown aetiology occur within 7 day follow previous vaccination pertussiscontaining vaccine ; Fever &gt; = 40Â°C within 48 hour vaccination , due another identifiable cause ; Collapse shocklike state within 48 hour vaccination ; Convulsions without fever , occur within 3 day vaccination . Acute disease and/or fever time enrolment within 24 hour study vaccine administration .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>4 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>MMR</keyword>
	<keyword>dTpa-IPV</keyword>
	<keyword>Boostrix Polio</keyword>
	<keyword>Repevax</keyword>
	<keyword>Priorix</keyword>
</DOC>